AMGN vs BIIB: Comparing Amgen and Biogen Ahead of Key Earnings
Key Takeaways
- AMGN trades near $385 with upcoming Q2 2026 earnings expected on August 4, following Q1 revenue growth of 6% to $8.6 billion and consistent earnings beats.
- BIIB closed recently around $203 after reporting Q2 revenue of $2.74 billion (up 3.4% year-over-year) and non-GAAP EPS well above estimates, with mixed stock reactions including gains of nearly 6% on one session.
- Both companies operate in the biotechnology sector, but AMGN offers broader product diversification and a dividend yield of approximately 2.6%, while BIIB focuses on neuroscience with recent emphasis on Alzheimer’s pipeline updates.
- Recent market activity shows BIIB exhibiting higher volatility tied to clinical and earnings developments, contrasted with AMGN’s steadier positioning ahead of its report.
- Sector exposure remains similar for both, with sentiment influenced by pipeline progress, regulatory developments, and overall biotech market conditions in recent weeks.
Why This Comparison Matters
Amgen Inc. (AMGN) and Biogen Inc. (BIIB) represent two established biotechnology companies whose stocks attract attention from investors seeking exposure to innovative therapies in areas such as oncology, inflammation, and neuroscience. This comparison examines their recent performance, business profiles, and market positioning to assist portfolio managers, swing traders, and long-term holders evaluating relative opportunities within the healthcare sector. The analysis draws on verifiable developments from the past several weeks to highlight contrasts in momentum, risk profiles, and catalysts without forecasting future outcomes. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Amgen Overview and Recent Performance
Amgen develops and commercializes biologic medicines targeting serious illnesses, with key products spanning oncology, cardiovascular disease, and bone health. In recent market activity, the stock has traded near $385 following Q1 2026 results that showed total revenues rising 6% to $8.6 billion, driven by volume growth. The company maintains a dividend yield near 2.6% and a relatively low beta, reflecting defensive characteristics within the sector. Ahead of its Q2 2026 earnings release scheduled for August 4, investor focus centers on product sales trends and any updates to full-year guidance. Sentiment in recent weeks has remained measured, supported by the firm’s history of earnings beats and diversified revenue base. From what I see, the steadier profile stands out here.
Biogen Overview and Recent Performance
Biogen specializes in therapies for neurological and neurodegenerative conditions, including multiple sclerosis and Alzheimer’s disease research. Recent performance reflects Q2 2026 results with revenue of $2.74 billion, up 3.4% year-over-year, and non-GAAP earnings per share exceeding consensus estimates. The stock has shown volatility, including sessions with gains exceeding 5% linked to earnings optimism, alongside earlier pressure from clinical data releases. Year-to-date returns stand around 12.6%, with a one-year gain near 52%. Market sentiment in recent weeks has been shaped by pipeline developments and broader biotech rotation, contributing to fluctuating price action around the $200 level. I’m watching this closely for any further pipeline updates.
Head-to-Head Comparison
Amgen maintains a broader therapeutic portfolio and established cash flows that support dividends and share repurchases, contrasting with Biogen’s narrower focus on central nervous system disorders where clinical outcomes can drive sharper sentiment shifts. Recent momentum favors Amgen’s pre-earnings stability, while Biogen has experienced more pronounced reactions to quarterly results and trial updates. Risk factors differ notably: Amgen carries exposure to patent expirations and pricing pressures across multiple franchises, whereas Biogen faces binary events tied to Alzheimer’s and other late-stage assets. Sector exposure overlaps in biotechnology, yet market positioning varies with Amgen’s larger market capitalization providing relative scale and Biogen’s valuation reflecting higher growth optionality in select pipelines. Overall, trade-offs center on diversification versus concentrated upside potential in evolving therapeutic areas.
AI Insights on the Pair
Based on observable factors such as trend consistency, earnings visibility, and relative positioning in recent weeks, Tickeron’s AI models currently assign a modest probabilistic edge to AMGN due to steadier operational metrics and upcoming data clarity. This assessment remains subject to change with new information and reflects pattern analysis rather than directional certainty.
Using Tickeron AI Trading Bots for Further Research
In my own process, I often review Tickeron’s AI Trading Bots to test strategies across different market conditions and timeframes. These tools provide detailed statistics on win rates, drawdowns, and trade frequency, which helps me evaluate how various approaches might align with stocks like these. The bots cover a range of tactics suited to biotech volatility, and I find the data useful for refining my perspective before making decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
BIIB sees its Stochastic Oscillator ascending out of oversold territory
On July 15, 2026, the Stochastic Oscillator for BIIB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on BIIB as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on August 04, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 62 cases over the following month. The odds of a continued upward trend are .
BIIB moved above its 50-day moving average on July 23, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 174 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.630) is normal, around the industry mean (19.574). P/E Ratio (36.934) is within average values for comparable stocks, (31.205). Projected Growth (PEG Ratio) (5.013) is also within normal values, averaging (11.773). BIIB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (3.070) is also within normal values, averaging (4.087).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
Advertisement